Source-grounded facts extracted from DNA X, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
DNA X, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 22, 2026, the Company received a delisting determination letter from the Staff advising the Company that unless the Company requests a hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal Nasdaq’s delisting”
DNA X, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 22, 2026, the Company received a delisting determination letter from the Staff advising the Company that unless the Company requests a hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal Nasdaq’s delisting”
DNA X, Inc. engaged TAAD LLP as its auditor.
“On April 27, 2026, the Audit Committee approved the engagement of TAAD LLP (“TAAD”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
DNA X, Inc. dismissed Baker Tilly US, LLP as its auditor.
“On April 27, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of DNA X, Inc. (the “Company”) dismissed Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting firm.”
DNA X, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue There was no revenue from continuing operations.
“On April 14, 2026, DNA X, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2025”
DNA X, Inc.: Changed corporate name to DNA X, Inc. via certificate of amendment to certificate of incorporation (effective 2026-01-23).
“On the Closing Date, the Company changed its corporate name to DNA X, Inc. pursuant to a certificate of amendment to the Company’s amended and restated certificate of incorporation (the “ Charter Amendment ”) filed with the Delaware Secretary of State on January 23, 2026 (the “ Name Change ”).”
DNA X, Inc. terminated February Note with Streeterville Capital, LLC valued at approximately $5.4 million.
“On the Closing Date, the Company prepaid (i) that certain promissory note (the “ July Note ”), dated July 11, 2025, issued by the Company to Streeterville Capital, LLC (the “ Lender ”), pursuant to that certain note purchase agreement, dated July 11, 2025, by and between the Company and the Lender and (ii) that certain promissory note (the “ February Note ” and, together with the July Note, the “ Notes ”), dated February 21, 2025, issued by the Company to the Lender, pursuant to that certain note purchase agreement, dated February 21, 2025, by and between the Company and the Lender.”
DNA X, Inc. terminated July Note with Streeterville Capital, LLC valued at approximately $5.4 million.
“On the Closing Date, the Company prepaid (i) that certain promissory note (the “ July Note ”), dated July 11, 2025, issued by the Company to Streeterville Capital, LLC (the “ Lender ”), pursuant to that certain note purchase agreement, dated July 11, 2025, by and between the Company and the Lender and (ii) that certain promissory note (the “ February Note ” and, together with the July Note, the “ Notes ”), dated February 21, 2025, issued by the Company to the Lender, pursuant to that certain note purchase agreement, dated February 21, 2025, by and between the Company and the Lender.”
DNA X, Inc. amended APA Amendment with the Buyer, the Parent, and the Seller Representative.
“On the Closing Date, the Company, the Buyer, the Parent, and the Seller Representative entered into a second amendment to the Asset Purchase Agreement (the “ APA Amendment ”).”
DNA X, Inc. completed a disposition involving Pace Car Acquisition LLC (closed 2026-01-23).
“the completion on January 23, 2026 (the “ Closing Date ”) of the previously announced sale (the “ Asset Sale ”) of substantially all of its assets related to the enterprise 5G solutions business, including rugged handsets, smartphones, wireless internet device, software, services, and accessories by DNA X, Inc. (formerly, Sonim Technologies, Inc.), a Delaware corporation (the “ Company ”), to Pace Car Acquisition LLC, (the “ Buyer ”)”
DNA X, Inc. incurred convertible notes of $1,200,000 with DNA Holdings Venture, Inc. at 10% per annum maturing December 15, 2026.
“issued a convertible promissory note in the original principal amount of $1,200,000 (the “DNA Note”)”
DNA X, Inc. completed an acquisition involving DNA Holdings Venture, Inc. for 223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares of the Company’s common stock as of the date of issuance (closed 2025-12-15).
“the Company purchased 100% of the membership interests in DNA X LLC, a Delaware limited liability company, (“DNA X”) for an aggregate purchase price of 223,201 shares of the Company’s common stock, representing 19.99% of the outstanding shares of the Company’s common stock as of the date of issuance.”
DNA X, Inc.: Approved and effected a 1-for-18 reverse stock split of common stock via a certificate of amendment to the amended and restated certificate of incorporation (effective 2025-10-27).
“On October 20, 2025, the Company filed a certificate of amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Certificate of Amendment will become effective at 12:01 a.m. Eastern Time on October 27, 2025, at which time every eighteen (18) shares of Common Stock will be automatically combined into one (1) issued and outstanding share of Common Stock, without any change in par value per share.”
DNA X, Inc.: Amendment to increase authorized shares from 100,000,000 to 1,000,000,000 (effective 2025-10-16).
“On October 16, 2025, the Company effected the Authorized Share Proposal by filing a certificate of amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, effective as of such date.”
DNA X, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“October 17, 2025, the Company received written notification from Nasdaq (the “Extension Notice”) granting the Company an extension through December 31, 2025, to regain compliance with Nasdaq Listing Rule 5550(b)(1). Under the terms of the extension, on or before December 31, 2025, the Company must evidence compliance with Nasdaq Listing Rule 5550(b)(1) as set forth in the Extension Notice. The Company intends to satisfy these requirements within the current extension period or, if necessary, to request a further extension from Nasdaq, which would be subject to Nasdaq’s discretion. The Company”
DNA X, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
“October 17, 2025, the Company received written notification from Nasdaq (the “Extension Notice”) granting the Company an extension through December 31, 2025, to regain compliance with Nasdaq Listing Rule 5550(b)(1). Under the terms of the extension, on or before December 31, 2025, the Company must evidence compliance with Nasdaq Listing Rule 5550(b)(1) as set forth in the Extension Notice. The Company intends to satisfy these requirements within the current extension period or, if necessary, to request a further extension from Nasdaq, which would be subject to Nasdaq’s discretion. The Company”
DNA X, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).
“August 22, 2025, Sonim Technologies, Inc. (the “Company”) received a letter (the “Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2025 was $1,334”
DNA X, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“August 13, 2025, Sonim Technologies, Inc. (the “Company”) received a letter (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) for continued listing. The Bid Price Rule requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”) provides that a failure to meet the minimum bid price requirement ex”
DNA X, Inc. incurred debt of €3 million with Tradewind GmbH at the greater of 4.00% or EURIBOR plus 3.50% maturing twelve (12) months, subject to an automatic annual extension, unless terminated.
“Tradewind will provide receivables factoring to the Company. Pursuant to the terms of the Factoring Agreement, eligible receivables will be purchased by Tradewind at a 15% discount to their face value. The maximum financing amount of the factoring facility is €3 million.”
DNA X, Inc. incurred senior notes of $2,755,000 with Streeterville Capital, LLC at nine percent (9%) per annum maturing eighteen (18) months following the date of issuance.
“On July 11, 2025, Sonim Technologies, Inc. (the “Company”) entered into a note purchase agreement (the “Purchase Agreement”) with Streeterville Capital, LLC (the “Lender”) pursuant to which the Company issued and sold to the Lender a promissory note in the original principal amount of $2,755,000 (the “Note”).”
DNA X, Inc. engaged Baker Tilly US, LLP as its auditor.
“the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.”
Moss Adams LLP resigned as auditor of DNA X, Inc..
“Moss Adams has resigned as the auditors of the Company, and the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.